Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
OPTIMISE-CEEMEA is a multinational, multi-centre, observational, prospective study which will include patients suffering from diabetes type 2, treated or untreated, insulin dependent or not insulin dependent.
In this study we aim to explore at a primary care level whether the use of benchmarking against a set of guideline-based reference values on a patient basis, may improve quality of patient care, in particular control of diabetes, lipids and blood pressure.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with diabetes type 2 |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients in the benchmarking group achieving pre-set targets for HbA1c1 | To investigate whether the use of benchmarking could improve quality of patient care, in particular the control of diabetes, lipids and blood pressure, expressed as the percentage of patients in the benchmarking group achieving pre-set targets for HbA1c1 | after 12 months of follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| Quality of patient care improvement, in particular the control of diabetes, lipids and blood pressure | To investigate whether the use of benchmarking could improve quality of patient care, in particular the control of diabetes, lipids and blood pressure | after 12 months of follow-up versus baseline |
| Markers of preventive screening |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with diabetes type 2
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Dan Isacoff, ASSOC. PROF. | University of Medicine and Pharmacy Carol Davila, Bucharest, Romania | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Blagoevgrad | Bulgaria | ||||
| Research Site |
Not provided
Not provided
Not provided
Not provided
To follow up evolution markers of preventive screening; retinopathy, neuropathy, dietary counseling, smoking habits, BMI, waist circumference, physical activity |
| after 12 months of follow-up versus baseline |
| The LDL cholesterol parameter of the primary and secondary objectives according to ATP III guidelines | To investigate the LDL cholesterol parameter of the primary and secondary objectives according to ATP III guidelines | after 12 months of follow-up versus baseline |
| Pleven |
| Bulgaria |
| Research Site | Plovdiv | Bulgaria |
| Research Site | Sofia | Bulgaria |
| Research Site | Alexandria | Romania |
| Research Site | Brasov | Romania |
| Research Site | Bucharest | Romania |
| Research Site | Cluj-Napoca | Romania |
| Research Site | Constanța | Romania |
| Research Site | Craiova | Romania |
| Research Site | Galati | Romania |
| Research Site | Giurgiu | Romania |
| Research Site | Iași | Romania |
| Research Site | Oradea | Romania |
| Research Site | Piteşti | Romania |
| Research Site | Ploieşti | Romania |
| Research Site | Satu Mare | Romania |
| Research Site | Tg Jiu | Romania |
| Research Site | Tg Mures | Romania |
| Research Site | Timișoara | Romania |
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided